FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040374582> ?p ?o ?g. }

• W2040374582 endingPage "56.e11" @default.
• W2040374582 startingPage "49" @default.
• W2040374582 abstract "BackgroundRandomized trials provide evidence to inform treatment decisions. The Consolidated Standards of Reporting Trials (CONSORT) Statement is a set of recommendations for the reporting of trials.ObjectiveWe sought to assess the quality of reporting allergen-specific immunotherapy trials according to CONSORT criteria.MethodsThe reporting of the procedure, randomization, dropouts, strict conduct of intention-to-treat (ITT) analysis, and sample size calculation according to CONSORT were assessed in the 46 subcutaneous and 48 sublingual immunotherapy (SLIT) blind, placebo-controlled randomized trials published between 1996 and 2009 in English.ResultsOne subcutaneous immunotherapy (2.2%) and 3 SLIT (6.6%) trials met CONSORT Statement criteria. These were used for the registration of sublingual tablets to the European Medicines Agency. In subcutaneous immunotherapy, 16 (35%) studies reported a CONSORT flow chart, and 12 (26%) provided a description of dropouts. Adequate randomization was reported in 9 (35%) studies, and incomplete randomization was reported in 15 (33%). Power analysis was reported in 15 (33%) studies. In SLIT, 20 (42%) studies reported a CONSORT flow chart, and 16 (32%) a description of dropouts. ITT analysis was carried out in 1 (2.2%) SLIT study, and a modified ITT analysis was used in 1 (2.2%) subcutaneous immunotherapy study and 2 (4.4%) SLIT studies. Adequate randomization was reported in 6 (12%) studies, and incomplete randomization was reported in 16 (32%). Power analysis was reported in 15 (27%) studies.ConclusionAs in other areas of medicine, the quality of reporting of most immunotherapy trials is low, and only 4.2% of SLIT randomized controlled trials met all of the criteria of the CONSORT Statement. Use of the CONSORT criteria should be encouraged. Randomized trials provide evidence to inform treatment decisions. The Consolidated Standards of Reporting Trials (CONSORT) Statement is a set of recommendations for the reporting of trials. We sought to assess the quality of reporting allergen-specific immunotherapy trials according to CONSORT criteria. The reporting of the procedure, randomization, dropouts, strict conduct of intention-to-treat (ITT) analysis, and sample size calculation according to CONSORT were assessed in the 46 subcutaneous and 48 sublingual immunotherapy (SLIT) blind, placebo-controlled randomized trials published between 1996 and 2009 in English. One subcutaneous immunotherapy (2.2%) and 3 SLIT (6.6%) trials met CONSORT Statement criteria. These were used for the registration of sublingual tablets to the European Medicines Agency. In subcutaneous immunotherapy, 16 (35%) studies reported a CONSORT flow chart, and 12 (26%) provided a description of dropouts. Adequate randomization was reported in 9 (35%) studies, and incomplete randomization was reported in 15 (33%). Power analysis was reported in 15 (33%) studies. In SLIT, 20 (42%) studies reported a CONSORT flow chart, and 16 (32%) a description of dropouts. ITT analysis was carried out in 1 (2.2%) SLIT study, and a modified ITT analysis was used in 1 (2.2%) subcutaneous immunotherapy study and 2 (4.4%) SLIT studies. Adequate randomization was reported in 6 (12%) studies, and incomplete randomization was reported in 16 (32%). Power analysis was reported in 15 (27%) studies. As in other areas of medicine, the quality of reporting of most immunotherapy trials is low, and only 4.2% of SLIT randomized controlled trials met all of the criteria of the CONSORT Statement. Use of the CONSORT criteria should be encouraged." @default.
• W2040374582 created "2016-06-24" @default.
• W2040374582 creator A5004878337 @default.
• W2040374582 creator A5009413838 @default.
• W2040374582 creator A5020135918 @default.
• W2040374582 creator A5025157783 @default.
• W2040374582 creator A5030629710 @default.
• W2040374582 creator A5038530868 @default.
• W2040374582 creator A5043192106 @default.
• W2040374582 creator A5046881136 @default.
• W2040374582 creator A5048797041 @default.
• W2040374582 creator A5055677585 @default.
• W2040374582 creator A5064146791 @default.
• W2040374582 creator A5069959810 @default.
• W2040374582 creator A5071868716 @default.
• W2040374582 creator A5073839386 @default.
• W2040374582 creator A5075387555 @default.
• W2040374582 creator A5080241969 @default.
• W2040374582 creator A5083725831 @default.
• W2040374582 creator A5087981381 @default.
• W2040374582 date "2011-01-01" @default.
• W2040374582 modified "2023-10-18" @default.
• W2040374582 title "The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA2LEN) article" @default.
• W2040374582 cites W120984530 @default.
• W2040374582 cites W1600513579 @default.
• W2040374582 cites W1921245875 @default.
• W2040374582 cites W1964354442 @default.
• W2040374582 cites W1964367449 @default.
• W2040374582 cites W1964893966 @default.
• W2040374582 cites W1965377999 @default.
• W2040374582 cites W1968350578 @default.
• W2040374582 cites W1969658977 @default.
• W2040374582 cites W1973050649 @default.
• W2040374582 cites W1974103230 @default.
• W2040374582 cites W1974582619 @default.
• W2040374582 cites W1981637609 @default.
• W2040374582 cites W1984052453 @default.
• W2040374582 cites W1984574173 @default.
• W2040374582 cites W1984780114 @default.
• W2040374582 cites W1984973837 @default.
• W2040374582 cites W1986404685 @default.
• W2040374582 cites W1986517239 @default.
• W2040374582 cites W1988281337 @default.
• W2040374582 cites W1988632600 @default.
• W2040374582 cites W1988732284 @default.
• W2040374582 cites W1990451108 @default.
• W2040374582 cites W1990995622 @default.
• W2040374582 cites W1993440776 @default.
• W2040374582 cites W1993555827 @default.
• W2040374582 cites W1996748765 @default.
• W2040374582 cites W1997120806 @default.
• W2040374582 cites W1997289406 @default.
• W2040374582 cites W1998207718 @default.
• W2040374582 cites W2004804859 @default.
• W2040374582 cites W2005704343 @default.
• W2040374582 cites W2005932415 @default.
• W2040374582 cites W2008023699 @default.
• W2040374582 cites W2010986485 @default.
• W2040374582 cites W2013532938 @default.
• W2040374582 cites W2016063789 @default.
• W2040374582 cites W2017662463 @default.
• W2040374582 cites W2017910324 @default.
• W2040374582 cites W2018309112 @default.
• W2040374582 cites W2027282910 @default.
• W2040374582 cites W2028280773 @default.
• W2040374582 cites W2028792363 @default.
• W2040374582 cites W2030014293 @default.
• W2040374582 cites W2031107991 @default.
• W2040374582 cites W2032541700 @default.
• W2040374582 cites W2032982186 @default.
• W2040374582 cites W2033232206 @default.
• W2040374582 cites W2042336351 @default.
• W2040374582 cites W2042506161 @default.
• W2040374582 cites W2042555734 @default.
• W2040374582 cites W2043994368 @default.
• W2040374582 cites W2046241981 @default.
• W2040374582 cites W2047418056 @default.
• W2040374582 cites W2049494708 @default.
• W2040374582 cites W2051493108 @default.
• W2040374582 cites W2051838691 @default.
• W2040374582 cites W2052331305 @default.
• W2040374582 cites W2052490983 @default.
• W2040374582 cites W2057086738 @default.
• W2040374582 cites W2059013940 @default.
• W2040374582 cites W2060411425 @default.
• W2040374582 cites W2062236488 @default.
• W2040374582 cites W2066871437 @default.
• W2040374582 cites W2069096507 @default.
• W2040374582 cites W2072867511 @default.
• W2040374582 cites W2073342172 @default.
• W2040374582 cites W2077247933 @default.
• W2040374582 cites W2078463005 @default.
• W2040374582 cites W2080653630 @default.
• W2040374582 cites W2083008609 @default.
• W2040374582 cites W2087437629 @default.
• W2040374582 cites W2089792148 @default.
• W2040374582 cites W2089908284 @default.
• W2040374582 cites W2092203805 @default.

• next